Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical…
Biotechnology
US, Pittsburgh [HQ]
Cash Flow Statements
8 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Cash Flow (OCF) | -1.00 | -3.00 | -9.00 | -18.00 | -26.00 | -47.00 | -100.00 | -88.00 | |
| Operating Cash (Net) | -1.00 | -3.00 | -9.00 | -18.00 | -26.00 | -47.00 | -100.00 | -88.00 | |
| Accounts Receivable | - - | - - | - - | - - | - - | - - | - - | -42.00 | |
| Accounts Payable | - - | - - | - - | - - | - - | - - | -1.00 | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | |
| Change | - - | - - | - - | -1.00 | - - | 2.00 | 2.00 | -37.00 | |
| Other WC | - - | - - | - - | -1.00 | - - | 1.00 | 4.00 | 8.00 | |
| Investing Activities | |||||||||
| Used Cash (Net) | - - | - - | -10.00 | -4.00 | -11.00 | -226.00 | -114.00 | 82.00 | |
| Capital Expenditure | - - | - - | -2.00 | -6.00 | -14.00 | -68.00 | -52.00 | -11.00 | |
| Purchases of Investments | - - | - - | -8.00 | -9.00 | -3.00 | -190.00 | -318.00 | -508.00 | |
| Sale/Maturity of Investment | - - | - - | - - | 10.00 | 6.00 | 32.00 | 257.00 | 503.00 | |
| Property, Plant, Equipment (P&PE) | - - | - - | -2.00 | -6.00 | -14.00 | -68.00 | -52.00 | -11.00 | |
| Acquisitions (Net) | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Investing Activities | - - | - - | - - | - - | - - | - - | - - | 100.00 | |
| Financing Activities | |||||||||
| Used Cash (Net) | -3.00 | -51.00 | -73.00 | -107.00 | -118.00 | -347.00 | -35.00 | -202.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | - - | - - | |
| Issued | - - | 42.00 | 73.00 | 107.00 | 118.00 | 355.00 | 35.00 | 203.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | 3.00 | 9.00 | - - | - - | - - | -7.00 | - - | - - | |
| Cash Balances | |||||||||
| Begin of Period | - - | 1.00 | 49.00 | 103.00 | 187.00 | 268.00 | 341.00 | 161.00 | |
| End of Period | 1.00 | 49.00 | 103.00 | 187.00 | 268.00 | 341.00 | 161.00 | 358.00 | |
| Change | 1.00 | 47.00 | 54.00 | 83.00 | 80.00 | 72.00 | -179.00 | 196.00 | |
| Non-Cash Balances | |||||||||
| Depreciation and Amortization | - - | - - | - - | - - | 1.00 | 2.00 | 4.00 | 5.00 | |
| Stock Based Compensation | - - | - - | - - | 1.00 | 3.00 | 15.00 | 33.00 | 39.00 | |
| Other | - - | 3.00 | - - | - - | - - | 1.00 | - - | -153.00 | |
| Highlighted metrics | |||||||||
| Free Cash Flow (FCF) | -1.00 | -4.00 | -11.00 | -25.00 | -40.00 | -116.00 | -153.00 | -100.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | - - | - - | - - | - - | 431.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - |